aTyr Pharma (NASDAQ:LIFE) Releases Earnings Results, Beats Estimates By $0.01 EPS

aTyr Pharma (NASDAQ:LIFE) announced its earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01, Yahoo Finance reports. The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.11 million.

aTyr Pharma Stock Up 0.6 %

Shares of NASDAQ:LIFE traded up $0.01 during midday trading on Friday, hitting $1.61. The stock had a trading volume of 258,232 shares, compared to its average volume of 367,840. The company has a quick ratio of 6.27, a current ratio of 6.27 and a debt-to-equity ratio of 0.02. The business’s 50-day simple moving average is $1.77 and its 200-day simple moving average is $1.55. aTyr Pharma has a 12 month low of $1.08 and a 12 month high of $2.70. The company has a market cap of $109.38 million, a P/E ratio of -1.79 and a beta of 1.27.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada decreased their price target on shares of aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, March 15th. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of aTyr Pharma in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, aTyr Pharma has a consensus rating of “Hold” and an average price target of $23.67.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.